The ATP-competitive inhibitor, dinaciclib, exhibited IC50 sub 4 nM against a broad spectrum of CDKs (1, 2, 5, and 9) and RB phosphorylation in BC cell lines, simultaneously with induction of apoptosis, all of which was better compared to flavopiridol. This evidence concerns the gene RB1 and breast cancer.